Innate Pharma S.A. (OTCMKTS:IPHYF) Short Interest Update

Innate Pharma S.A. (OTCMKTS:IPHYF) was the recipient of a significant drop in short interest in the month of August. As of August 31st, there was short interest totalling 4,900 shares, a drop of 21.0% from the August 15th total of 6,200 shares. Based on an average daily volume of 200 shares, the days-to-cover ratio is currently 24.5 days.

Innate Pharma Price Performance

OTCMKTS:IPHYF remained flat at $2.30 during midday trading on Tuesday. The business’s 50 day moving average price is $2.10 and its 200-day moving average price is $2.33. Innate Pharma has a 1-year low of $1.93 and a 1-year high of $3.00.

About Innate Pharma

Innate Pharma SA, a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager.